Verisante Technology Signs Distribution Deal in Switzerland for Cancer Detection Technology

Verisante Technology Signs Distribution Deal in Switzerland for Cancer Detection Technology

By: AllPennyStocks.com News

Tuesday, February 19, 2013

When people think of cancer, usually the first thing that springs to mind is that of the lungs because it is so widely publicized as a leading killer globally and because so many pharmaceutical companies are targeting the indication for development of new therapies. But, melanoma, the most dangerous type of skin cancer and leading cause of death from skin disease (about 75 percent), is nothing to mess with either. Globally, about 160,000 cases are diagnosed each year and, according to the World Health Organization, about 48,000 deaths worldwide are the result of melanoma. Switzerland has the third highest skin cancer rate in the world, behind only Australia and New Zealand. In Europe, there are more cases of melanoma diagnosed in Switzerland each year than any other country, with 22 new cases each year per 100,000 citizens. Worse yet, the number of malignant melanoma cases has doubled in the past two decades.


As with any other form of cancer, early diagnosis is critical in minimizing morbidity and mortality rates.

Vancouver’s Verisante Technology, Inc. (TSX-Venture:VRS) is aiming to do something about the problem with their Aura™ early cancer detection technology. The company also has the Verisante Core™ series for lung, colon and cervical cancer detection. The early cancer detection platform – which was developed by the British Columbia Cancer Agency – is the same for each, but the software and non-evasive probes are unique to each device.

The technology has earned Verisante numerous awards, including Core, which has still not garnered marketing clearance anywhere in the world, being named a Top 10 breakthrough of 2011 by the Canadian Cancer Society.

The Aura technology, which delivers immediate results to physicians, has been approved for use in Canada, Europe and Australia. At more than $78 billion, the European medical device market is the second largest in the world, only behind the U.S. Aura™ is an optical system that uses Raman spectroscopy to biochemically analyze the skin.

Tuesday, Verisante took a stride down the revenue path with a new exclusive agreement with award-winning Pacifica Handels AG for distribution of Aura in Switzerland.

"Pacifica knows the market for dermatological and skin care devices in Switzerland intimately, and this specialized knowledge in a country that has the third highest skin cancer rate in the world will be extremely helpful with market penetration,” said Thomas Braun, President and CEO of Verisante.

With the new agreement, Baar, Switzerland-based Pacifica will add Aura to its product line that includes medical laser and IPL systems for use in aesthetics, dermatology, and other applications.

Dr. Heiner Grönewald, Managing Director of Pacifica, commented that he was impressed with the clinical results of Aura and that it can assist in dealing with the skin cancer “epidemic” in Switzerland.

Shares of VRS did not respond favorably to the news today, closing the day mildly down by one penny, or 1.79 percent, at 55 cents per share; bringing shares back basically even so far in 2013.

Copyright © 2013 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Miner Scores with Acquisition of Promising Silver District in Mexico
Mixed Signals: Durable Goods Orders Up, But Not All Sectors Are Soaring
Biotech Steals The Show Following Pre-Clinical Data Announcement
Most Popular
FREE Newsletter


Back to Top